Cohort of Patients With Chronic Myelomonocytic Leukemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Sampling.
- Who it may be relevant to
- Registry conditions: Leukemia, Myelomonocytic Leukemia, Chronic. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data. Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.
Interventions
- Biological Sampling
Blood samples taken as part of a scheduled assessment within the context of medical care * Standard sample: 2 x 10 mL EDTA tubes * For the initial assessment: 1 x 10 mL dry tube At the request of the research teams: one EDTA tube may be replaced by a heparinised or citrated tube, depending on the planned research. Bone marrow samples, taken during a scheduled myelogram as part of medical care * Myelogram: 1 x 2 mL EDTA tube In exceptional cases, during a scheduled surgical procedure, a tissue s
Primary outcome measures
- Understanding the pathophysiology of chronic myelomonocytic leukaemia [Time frame: through study completion, an average of 15 years]
Eligibility criteria
Inclusion criteria
- Adults aged 18 years and over
- Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or
- Confirmed diagnosis of chronic myelomonocytic leukemia
- Regardless of stage (chronic or transformed), and whether or not currently being treated
- Signed informed consent
Exclusion criteria
- Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV)
- Refusal informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 24 centers
- CHU Amiens Picardie — Amiens
- CHU Angers — Angers
- Hôpital Privé Antony — Antony
- AP-HP Hôpital Avicenne — Bobigny
- Centre Hospitalier Sud Francilien — Corbeil-Essonnes
- CHU Grenoble — Grenoble
- AP-HP Hôpital Bicêtre — Le Kremlin-Bicêtre
- CHRU Lille Hôpital Claude Huriez — Lille
- … and 16 more centers
Identifiers
NCT: NCT07512882 · 2025-A02438-41 · CSET number 2025/4169